Sedogen Secures Patent, Offering New Hope for Prader-Willi Syndrome Behavioral Treatment

CHICAGO, IL – April 15, 2026 – In a move that underscores a deep, personal commitment to the rare disease community, biopharmaceutical company Sedogen LLC announced it has been issued a new U.S. patent for the use of a diazoxide formulation to treat the challenging behavioral symptoms associated with Prader-Willi syndrome (PWS). The patent offers intellectual property protection for a potential therapy aimed at mitigating the relentless food-seeking behaviors and preoccupation with food that define the condition.

The patent (12,589,098), issued on March 31, 2026, is a significant milestone for the parent-led company. For families affected by PWS, it represents another potential tool in a long and arduous battle against the syndrome's most difficult aspects.

"My daughter was the first individual living with PWS that was treated with diazoxide, dating back to 2013," said Sara Cotter, Founder and President of Sedogen, in a press release. "I'm thrilled that this patent was issued after much effort, strengthening our commitment to serve the Prader-Willi syndrome community."

A Complex Condition Meets a Repurposed Drug

Prader-Willi syndrome is a rare and complex genetic disorder occurring in approximately 1 in 16,000 births. It results from the lack of expression of certain paternal genes on chromosome 15, leading to a cascade of physiological and developmental challenges. While the syndrome includes developmental delays, growth hormone deficiency, and intellectual disability, its most formidable symptom is hyperphagia—an insatiable, torturous hunger that cannot be satisfied.

This unrelenting drive to eat forces families into a state of constant vigilance, often requiring them to lock refrigerators and food cabinets to prevent life-threatening obesity. The behavioral manifestations extend beyond hunger, encompassing emotional outbursts, stubbornness, and obsessive-compulsive tendencies, making daily life profoundly challenging for both individuals with PWS and their caregivers.

Enter diazoxide, a drug with a long medical history. First approved in the 1970s, it has been a frontline treatment for specific forms of hypoglycemia (dangerously low blood sugar) by acting on ATP-sensitive potassium (K+ ATP) channels in the pancreas to reduce insulin secretion. Now, researchers believe this same mechanism may hold the key to alleviating PWS symptoms. The scientific rationale suggests that by activating these same channels in the hypothalamus—the brain's appetite control center—diazoxide could help correct the faulty neural signaling that drives hyperphagia.

Navigating a Growing PWS Treatment Pipeline

Sedogen’s development does not occur in a vacuum. The landscape of PWS therapeutics has become a hotbed of research and innovation, a stark contrast to decades past when families had few options beyond strict diet and behavioral management. The current standard of care is a multidisciplinary approach involving growth hormone therapy to improve muscle mass and stature, along with physical, occupational, and behavioral therapies.

However, the race to develop a pharmacological solution for hyperphagia has intensified. A major breakthrough occurred in March 2025 with the FDA approval of Vykat XR (diazoxide choline) from Soleno Therapeutics, the first-ever drug specifically sanctioned to treat hyperphagia in PWS. This approval validated the potential of diazoxide as a therapeutic agent for the PWS community and set a new benchmark for treatment.

Beyond diazoxide, the pipeline is robust. Harmony Biosciences is in Phase 3 trials with pitolisant, which targets excessive daytime sleepiness and has shown promise in reducing hyperphagia and irritability. Acadia Pharmaceuticals is also in late-stage trials with a carbetocin nasal spray, which modulates the brain’s oxytocin system to regulate hunger. Other approaches, including GLP-1 receptor agonists and even early-stage genetic therapies, are also under investigation, reflecting a multi-pronged assault on the syndrome.

Sedogen’s new patent carves out a specific niche in this competitive but collaborative field, focusing on its own unique formulation and method for using diazoxide to address behavioral symptoms.

The Strategic Value of a Patent in Rare Disease

For a small, parent-led company like Sedogen, securing a patent is more than a legal formality; it is a strategic lifeline. The world of orphan drugs—therapies for diseases affecting fewer than 200,000 people—operates under a different set of economic rules. The small patient populations make it difficult to recoup the enormous costs of drug development.

Intellectual property protection, like the patent granted to Sedogen, provides a period of market exclusivity, which is crucial for attracting investment and funding the expensive, multi-phase clinical trials required for FDA approval. The patent, which expires in June 2034, gives the company a protected runway to advance its specific therapeutic approach without the immediate threat of generic competition.

This protection is essential for fostering innovation in areas of high unmet need. It allows companies to take risks on novel scientific theories and pursue treatments that might otherwise be considered commercially unviable, ultimately benefiting the patient communities they aim to serve.

A Parent-Led Quest for a Better Quality of Life

The story of Sedogen is emblematic of a powerful trend in the rare disease space: patient- and parent-driven drug development. Sara Cotter's journey, beginning with her daughter's treatment in 2013 and culminating in this patent, highlights a deeply personal mission. This intimate understanding of the daily struggles of living with PWS provides a unique and powerful motivation that resonates throughout the community.

While new drugs offer immense hope, the unmet needs remain vast. Families still navigate a world of complex dietary restrictions, behavioral interventions, and emotional strain. The ultimate goal is not just to manage a single symptom, but to improve the overall quality of life, foster greater independence, and alleviate the constant anxiety that accompanies the syndrome.

Sedogen’s patent represents a tangible step in this long journey. It transforms a parent’s determined search for a solution into a protected, developable asset that has the potential to help countless others. For the tight-knit PWS community, this news is a welcome sign that the fight continues on all fronts, driven by both large pharmaceutical companies and the unwavering dedication of those with the most personal stake in the outcome.